AMICUS THERAPEUTICS INC's ticker is FOLD and the CUSIP is 03152W109. A total of 277 filers reported holding AMICUS THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 0.99 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,824,596 | +28.1% | 150,049 | +32.3% | 0.00% | 0.0% |
| Q2 2023 | $1,424,053 | +15.3% | 113,380 | +1.8% | 0.00% | 0.0% |
| Q1 2023 | $1,235,115 | -8.1% | 111,372 | +1.2% | 0.00% | 0.0% |
| Q4 2022 | $1,343,698 | +17.8% | 110,049 | +0.7% | 0.00% | 0.0% |
| Q3 2022 | $1,141,123 | -4.5% | 109,303 | -1.8% | 0.00% | 0.0% |
| Q2 2022 | $1,194,836 | +15.7% | 111,251 | +2.0% | 0.00% | 0.0% |
| Q1 2022 | $1,032,940 | -33.4% | 109,075 | -18.8% | 0.00% | 0.0% |
| Q4 2021 | $1,551,000 | +19.4% | 134,323 | -1.3% | 0.00% | 0.0% |
| Q3 2021 | $1,299,000 | -9.3% | 136,033 | -8.5% | 0.00% | 0.0% |
| Q2 2021 | $1,432,000 | -0.2% | 148,592 | +2.3% | 0.00% | 0.0% |
| Q1 2021 | $1,435,000 | -59.5% | 145,275 | -5.2% | 0.00% | -66.7% |
| Q4 2020 | $3,540,000 | +70.6% | 153,292 | +4.3% | 0.00% | +50.0% |
| Q3 2020 | $2,075,000 | -11.7% | 146,973 | -2.8% | 0.00% | 0.0% |
| Q2 2020 | $2,349,000 | +56.7% | 151,174 | -6.8% | 0.00% | 0.0% |
| Q1 2020 | $1,499,000 | +0.3% | 162,267 | +5.7% | 0.00% | 0.0% |
| Q4 2019 | $1,495,000 | +19.4% | 153,508 | -1.1% | 0.00% | +100.0% |
| Q3 2019 | $1,252,000 | -34.5% | 155,247 | +1.5% | 0.00% | -50.0% |
| Q2 2019 | $1,910,000 | +14.3% | 152,991 | +24.5% | 0.00% | 0.0% |
| Q1 2019 | $1,671,000 | +34.8% | 122,920 | -5.0% | 0.00% | 0.0% |
| Q4 2018 | $1,240,000 | -16.2% | 129,456 | +5.8% | 0.00% | 0.0% |
| Q3 2018 | $1,480,000 | -31.8% | 122,415 | -11.9% | 0.00% | 0.0% |
| Q2 2018 | $2,170,000 | +3.3% | 138,938 | -0.5% | 0.00% | 0.0% |
| Q1 2018 | $2,100,000 | +14.9% | 139,617 | +9.9% | 0.00% | 0.0% |
| Q4 2017 | $1,827,000 | -3.3% | 127,025 | +1.3% | 0.00% | 0.0% |
| Q3 2017 | $1,890,000 | +68.1% | 125,348 | +12.4% | 0.00% | +100.0% |
| Q2 2017 | $1,124,000 | +41.2% | 111,568 | -0.0% | 0.00% | 0.0% |
| Q1 2017 | $796,000 | +63.4% | 111,612 | +13.7% | 0.00% | 0.0% |
| Q4 2016 | $487,000 | -25.3% | 98,156 | +11.5% | 0.00% | 0.0% |
| Q3 2016 | $652,000 | +35.3% | 88,038 | -0.4% | 0.00% | 0.0% |
| Q2 2016 | $482,000 | -75.3% | 88,351 | -63.9% | 0.00% | -50.0% |
| Q1 2016 | $1,954,000 | -17.0% | 244,576 | +0.7% | 0.00% | 0.0% |
| Q4 2015 | $2,355,000 | -30.4% | 242,792 | +0.4% | 0.00% | -50.0% |
| Q3 2015 | $3,384,000 | -8.1% | 241,935 | -7.1% | 0.00% | 0.0% |
| Q2 2015 | $3,683,000 | +14065.4% | 260,295 | +10651.5% | 0.00% | – |
| Q1 2015 | $26,000 | +30.0% | 2,421 | 0.0% | 0.00% | – |
| Q4 2014 | $20,000 | +900.0% | 2,421 | +589.7% | 0.00% | – |
| Q3 2014 | $2,000 | +100.0% | 351 | 0.0% | 0.00% | – |
| Q2 2014 | $1,000 | 0.0% | 351 | 0.0% | 0.00% | – |
| Q1 2014 | $1,000 | 0.0% | 351 | 0.0% | 0.00% | – |
| Q4 2013 | $1,000 | -83.3% | 351 | -85.9% | 0.00% | – |
| Q3 2013 | $6,000 | 0.0% | 2,484 | 0.0% | 0.00% | – |
| Q2 2013 | $6,000 | – | 2,484 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Palo Alto Investors LP | 10,524,022 | $127,972,108 | 12.11% |
| Perceptive Advisors | 27,692,917 | $336,745,870 | 11.23% |
| Redmile Group, LLC | 16,944,621 | $206,046,591 | 9.80% |
| Finepoint Capital LP | 1,489,025 | $18,106,544 | 9.02% |
| CM Management, LLC | 450,000 | $5,472,000 | 5.81% |
| Avoro Capital Advisors LLC | 27,400,000 | $333,184,000 | 5.20% |
| MPM BioImpact LLC | 716,139 | $8,708,250 | 2.32% |
| Artal Group S.A. | 4,062,567 | $49,401 | 2.12% |
| SECTORAL ASSET MANAGEMENT INC | 803,464 | $9,770,122 | 1.90% |
| GREAT POINT PARTNERS LLC | 857,000 | $10,421,120 | 1.90% |